Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Catriona Yale Sells 9,074 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Catriona Yale sold 9,074 shares of the company’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $29.11, for a total transaction of $264,144.14. Following the completion of the sale, the insider now directly owns 95,648 shares in the company, valued at $2,784,313.28. This trade represents a 8.66 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Catriona Yale also recently made the following trade(s):

• On Friday, November 15th, Catriona Yale sold 9,061 shares of Akero Therapeutics stock. The shares were sold at an average price of $27.73, for a total value of $251,261.53.
• On Friday, November 1st, Catriona Yale sold 15,485 shares of Akero Therapeutics stock. The shares were sold at an average price of $32.62, for a total transaction of $505,120.70.
• On Wednesday, October 30th, Catriona Yale sold 4,515 shares of Akero Therapeutics stock. The shares were sold at an average price of $32.53, for a total transaction of $146,872.95.
• On Monday, October 14th, Catriona Yale sold 6,136 shares of Akero Therapeutics stock. The shares were sold at an average price of $30.03, for a total transaction of $184,264.08.
• On Friday, September 20th, Catriona Yale sold 5,500 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.65, for a total transaction of $152,075.00.

Akero Therapeutics Stock Down 6.2 %

Shares of NASDAQ:AKRO opened at $28.71 on Thursday. Akero Therapeutics, Inc. has a 1-year low of $15.32 and a 1-year high of $37.00. The company’s fifty day moving average is $30.91 and its two-hundred day moving average is $27.36. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25. The stock has a market capitalization of $2.00 billion, a price-to-earnings ratio of -7.66 and a beta of -0.23.

Akero Therapeutics (NASDAQ:AKRO) last issued its earnings results on Friday, November 8th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.15). Equities analysts anticipate that Akero Therapeutics, Inc. will post -3.96 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on AKRO shares. HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Akero Therapeutics in a research note on Monday, November 18th. Citigroup initiated coverage on shares of Akero Therapeutics in a research report on Monday, November 18th. They set a “buy” rating and a $65.00 price target for the company. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $46.83.

Institutional Trading of Akero Therapeutics

Large investors have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. grew its position in Akero Therapeutics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company’s stock worth $71,000 after purchasing an additional 446 shares during the last quarter. Eastern Bank acquired a new position in shares of Akero Therapeutics during the third quarter worth approximately $100,000. Summit Financial Wealth Advisors LLC bought a new position in Akero Therapeutics in the 3rd quarter worth approximately $205,000. Victory Capital Management Inc. acquired a new stake in Akero Therapeutics in the 3rd quarter valued at approximately $211,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Akero Therapeutics during the 3rd quarter valued at $265,000.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.